// App-Quantinova.ai

OP0264 (2022) : IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

Researchers

Presenter

  • M. Dougados

Principal Investigators

  • C. Charles-Schoeman

  • Z. Szekanecz

  • J. T. Giles

  • S. R. Ytterberg

  • D. L. Bhatt

  • G. G. Koch

  • I. Vranic

  • J. Wu

  • C. Wang

  • K. Kwok

  • S. Menon

  • C. A. Connell

  • A. Yndestad

  • J. L. Rivas

  • M. H. Buch

Medical Centers

  • Hôpital Cochin. Assistance Publique - Hôpitaux de Paris, Department of Rheumatology, Paris, France

  • PRES Sorbonne Paris-Cité, INSERM (U1153): Clinical Epidemiology and Biostatistics, Paris, France

  • University of California Los Angeles, Division of Rheumatology, Department of Medicine, Los Angeles, CA, United States of America

  • University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary

  • Columbia University Vagelos College of Physicians and Surgeons, Division of Rheumatology, New York, NY, United States of America

  • Mayo Clinic, Rheumatology, Rochester, MN, United States of America

  • Brigham and Women’s Hospital and Harvard Medical School, Department of Cardiovascular Medicine, Boston, MA, United States of America

  • University of North Carolina at Chapel Hill. Dept Genetics, Chapel Hill, United States of America

  • Pfizer Ltd, Inflammation and Immunology, Tadworth, Surrey, United Kingdom

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Pfizer Inc, Inflammation and Immunology, Oslo, Norway

  • Pfizer Inc, Inflammation and Immunology, Paris, France

  • University of Manchester and NIHR Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom

Locations

  • France

  • United States

  • Hungary

  • United Kingdom

  • Norway

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Coronary Artery Disease

  • Myocardial infarction

  • Rheumatoid arthritis

  • Diabetes

  • Hypertension

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved